Table III.
Univariate and multivariate analyses of DFS and OS in all patients (n=306).
| DFS | OS | |||||||
|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||
| Index | HR | P-value | HR (95% CI) | P-value | HR | P-value | HR (95% CI) | P-value |
| Age | 0.763 | 0.267 | 0.873 | 0.623 | ||||
| Sex | 0.599 | 0.035 | 0.539 | 0.036 | ||||
| Hypertension | 1.325 | 0.284 | 1.082 | 0.795 | ||||
| Diabetes | 1.356 | 0.077 | 1.455 | 0.064 | ||||
| ALT | 1.274 | 0.135 | 0.999 | 0.439 | ||||
| AST | 1.076 | 0.673 | 1.000 | 0.822 | ||||
| Platelet count (≥100 vs. <100×109/l) | 0.489 | 0.022 | 0.665 | 0.240 | ||||
| PT (≤14 vs. >14 sec) | 1.139 | 0.430 | 1.047 | 0.815 | ||||
| TBIL (≤17 vs. >17 µmol/l) | 1.118 | 0.504 | 1.193 | 0.373 | ||||
| HBV DNA (≤2,000 vs. >2,000 IU/ml) | 1.325 | 0.284 | 1.196 | 0.356 | ||||
| AFP (≤100 vs. >100 ng/ml) | 1.310 | 0.077 | 1.052 | 0.026 | ||||
| TNM stage | ||||||||
| I | (Ref.) | (Ref.) | (Ref.) | (Ref.) | ||||
| II | 1.144 | 0.555 | 1.073 | 0.809 | ||||
| III | 1.781 | <0.001 | 2.220 | <0.001 | ||||
| ASA | ||||||||
| I | (Ref.) | (Ref.) | (Ref.) | (Ref.) | ||||
| II | 1.111 | 0.515 | 1.115 | 0.571 | ||||
| III | 1.785 | 0.097 | 0.955 | 0.929 | ||||
| Child-Pugh grade (A vs. B) | 0.919 | 0.661 | 0.708 | 0.151 | ||||
| Cirrhosis | 0.959 | 0.839 | 1.370 | 0.254 | ||||
| Ascites | 1.370 | 0.058 | 1.192 | 0.387 | ||||
| Tumor diameter (≤5 vs. >5 cm) | 2.069 | <0.001 | 1.725 | 0.002 | 2.377 | <0.001 | 1.746 | 0.010 |
| (1.229–2.419) | (1.142–2.668) | |||||||
| Tumor number (Multiple vs. solitary) | 1.985 | <0.001 | 1.751 | 0.001 | 2.122 | <0.001 | 1.739 | 0.006 |
| (1.253–2.446) | (1.175–2.573) | |||||||
| Venous invasion (Yes vs. no) | 1.960 | <0.001 | 1.668 | 0.001 | 2.280 | <0.001 | 1.819 | 0.002 |
| (1.223–2.277) | (1.254–2.638) | |||||||
| Tumor differentiation | ||||||||
| Well differentiated | (Ref.) | (Ref.) | (Ref.) | (Ref.) | ||||
| Moderately differentiated | 2.283 | 0.008 | 3.541 | 0.006 | ||||
| Poorly differentiated | 2.339 | 0.052 | 2.029 | 0.068 | ||||
| Intraoperative blood loss (≤1,000 vs. >1,000 ml) | 1.561 | 0.008 | 1.649 | 0.010 | ||||
| Intraoperative transfusion (Yes vs. no) | 1.453 | 0.015 | 1.640 | 0.007 | ||||
| TACE (≤3 vs. >3) | 1.102 | 0.653 | 0.861 | 0.578 | ||||
| CA125 (≤15 vs. >15 U/ml) | 1.597 | 0.002 | 2.112 | <0.001 | 1.709 | 0.005 | ||
| (1.177–2.482) | ||||||||
DFS, disease-free survival; OS, overall survival; HBV, hepatitis B virus; ASA, American Society of Anesthesiologists; TNM, Tumor-Node-Metastasis; ALT, alanine aminotransferase; AST, aspartate aminotransferase; PT, prothrombin time; TBIL, serum total bilirubin; AFP, α-fetoprotein; TACE, transcatheter arterial chemoembolization; CA125, cancer antigen 125; HR, hazard ratio; CI, confidence interval.